4D Molecular Therapeutics (FDMT) Competitors $4.10 -0.22 (-4.99%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$4.22 +0.13 (+3.17%) As of 07/3/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. SION, GYRE, PHAT, ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, and STOKShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Sionna Therapeutics (SION), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Its Competitors Sionna Therapeutics Gyre Therapeutics Phathom Pharmaceuticals AnaptysBio Immatics Trevi Therapeutics Nuvation Bio Day One Biopharmaceuticals GH Research Stoke Therapeutics Sionna Therapeutics (NASDAQ:SION) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend SION or FDMT? Sionna Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 81.69%. 4D Molecular Therapeutics has a consensus price target of $29.56, indicating a potential upside of 621.75%. Given 4D Molecular Therapeutics' higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.004D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do insiders & institutionals believe in SION or FDMT? 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 3.9% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor SION or FDMT? In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 6 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 1.15 beat 4D Molecular Therapeutics' score of 0.07 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SION or FDMT more profitable? Sionna Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Sionna Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A 4D Molecular Therapeutics -767,126.06%-33.26%-30.68% Which has better earnings & valuation, SION or FDMT? Sionna Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/A4D Molecular Therapeutics$40K4,743.03-$160.87M-$3.18-1.29 SummarySionna Therapeutics and 4D Molecular Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.42M$2.43B$5.56B$9.05BDividend YieldN/A1.78%5.24%3.99%P/E Ratio-1.299.0227.6520.23Price / Sales4,743.03680.43419.56119.26Price / CashN/A21.7726.2128.59Price / Book0.374.558.035.65Net Income-$160.87M$31.26M$3.18B$249.15M7 Day Performance6.64%3.25%2.93%3.28%1 Month Performance-5.86%3.46%1.72%3.95%1 Year Performance-80.64%0.77%34.39%20.98% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.2791 of 5 stars$4.10-5.0%$29.56+621.7%-80.6%$196.42M$40K-1.29120News CoverageAnalyst ForecastSIONSionna TherapeuticsN/A$17.35+9.5%$38.50+121.9%N/A$698.93MN/A0.0035Positive NewsInsider TradeGYREGyre Therapeutics0.0793 of 5 stars$7.35-0.9%N/A-34.5%$695.68M$105.76M367.6840PHATPhathom Pharmaceuticals3.5903 of 5 stars$9.59-1.5%$17.50+82.5%-14.9%$679.99M$55.25M-1.83110ANABAnaptysBio2.286 of 5 stars$22.20-1.2%$42.38+90.9%-2.8%$660.18M$91.28M-4.58100News CoverageInsider TradeIMTXImmatics2.4202 of 5 stars$5.38-0.9%$14.67+172.6%-52.0%$660.02M$168.65M-31.65260Positive NewsTRVITrevi Therapeutics3.2765 of 5 stars$5.47-2.7%$20.29+270.9%+128.5%$659.19MN/A-12.1620News CoverageAnalyst ForecastAnalyst RevisionNUVBNuvation Bio3.4398 of 5 stars$1.96+1.3%$7.17+266.6%-31.2%$656.71M$7.87M-0.8360High Trading VolumeDAWNDay One Biopharmaceuticals1.7011 of 5 stars$6.50+0.5%$30.57+370.3%-50.4%$655.82M$131.16M-9.1560Upcoming EarningsGHRSGH Research1.5715 of 5 stars$12.19-2.0%$32.00+162.5%+26.9%$647.23MN/A-15.4310News CoverageAnalyst UpgradeSTOKStoke Therapeutics4.0255 of 5 stars$11.35-2.4%$23.20+104.4%-12.5%$634.96M$190.91M14.37100News CoverageAnalyst Forecast Related Companies and Tools Related Companies SION Alternatives GYRE Alternatives PHAT Alternatives ANAB Alternatives IMTX Alternatives TRVI Alternatives NUVB Alternatives DAWN Alternatives GHRS Alternatives STOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTHIS IS IT. Your FINAL CHANCE. At midnight, our 82% OFF July 4th deal disappears FOREVER. The countdown ...Investors Alley | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FDMT Stock Alerts